Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice buying opp yesterday..next week should be interesting..
hi blue..i bought more yesterday as well albeit a more humble amount..but nonetheless I cannot pass it up when I see it below 8.00..and trading to provide a little cash flow makes sense..true you can sell too soon and miss a big run..and after holding this for so long I realized all the big runs I missed because I did not trade..so disparaging traders is very naïve..and it makes the manipulators job easier..we have begun to see revenue begin to flow into adxs..and we will see more deals like the amgen and celene deals as adxs LM platform shows it versatility as a custom engineered adjunct therapy as well as powerful standalone..and unlike currently approve immunotherapies at an affordable price point..i remain an enthusiastic supporter of adxs lm platfoem..I know it has much to offer humanity as well as smart, flexible investors..we have come a very long way and the time to reasonable sp eval is on the horizon..
Gog phase 2 interrupted study comes to mind..with the model showing 95% liklihood of same response in general pop..I have been waiting to see the axal approved for metastatic cervical cancer soon.
Next week we touch 9.00 maybe sooner..nice return on what you buy down here for a few days wait..stupid give away..but I'm not complaining..
Leave the money in bank or but at these sub 8 levels..but if course.
conference yesterday..price always falls on a conference day..seems as though shorts are weakening and cannot push it back sub 8 or even 8.0x except within small time/trading interval.
sold out my entire position yesterday.. many better options..will this ever be profitable..? maybe but not any time soon.
Shorts establishing early down momentum has failed..up afternoon..
if volume is from shorts covering..I think we may see another take down today..just more tree shaking..but it appears these are getting expensive..and stock demand is limiting downside..so new higher trading range coming.
Forgot to adjust warrants..closed up over 11%..
Have not seen 10% swings in a while..screaming trade me..buy below 8 wait a day or 2 or 3..sell.even I can do it. Can generate little income while waiting..key is buy 8 or lower..that opp may be disappearing. But will see range reset this week
Not many oops left to purchase below 8
noticed attempts last week to drop it below 8..andd only for a few shares then boom back above 8 almost as soon as it touched 8..wouuldn't mind seeing below 7 long enough to buy a share or two..
a bio with a immunological treatment for brain cancer finishing a very long awaited phase 3 trial..and it is .18..really..how much do you need to know..many treatments disappoint in phase 3..most never even get that far..way better odds than the spin of a roulette wheel..in the end its much simplier than that..how much can I afford to lose on the best opportunity I have seen in a while..really who cares what anybody else thinks..i am not trying to be popular I am trying to make money..
large tutes lending shares to shorts artificially increases the supply of shares against a constant of lower demand, share price falls..law of economics..no stretch at all to see large holders buying more shares..maybe even the ones they own and lent out..as the shares for sale are not identified as short shares..and even though they are borrowed are for sale...pretty basic way to lower average cost..so with shorted shares we have a 25% dilution..and when they are recalled we have big reduction in shares traded..for adxs a big reduction in shares traded seems difficult to imagine given there are very few shares traded now at these prices at this inflated share count.
would be good to get some comparative treatment cost estimates for hpv cancer..between current standard of care and axal treatments.
the market eval for adxs will self correct ..patience..
Ignatius its simple really lends the shares then buy more at a lower price..thats what we are all doing. without the additional short shares this would be impossible to manage the way it has been..
in casino you bet against the house..here you bet on the house..unless you are short an .18 stock with huge upside..thats the difference I see.
long term investors in adxs include short share sellers..it also seems a little odd adxs short interest volume has been at 25% of total share count for months..even when price dropped to circa 4.00 there was no rush to cover..just as now..in fact short interest increased at those levels..environment has allowed traders to flourish..while covering has not been a priority..buy and wait..buy and trade..think most folks have the share price pattern down to a somewhat predictable event..monthly volatility is very profitable here..but shares shorted has remained a constant..not much different than a year or so ago..and has remained impervious to constantly improving commercialization opportunities..
for a while now adxs has been about when not if..but I don't think there is any urgent financial need for milestone payments..clearly adxs is planning on having substantial additional capital available soon given the announced short term future plans..and having that funding source will encourage short owners to reverse not wanting to give company away at these depressed prices..
whatever happens I would rather be sorry I did than sorry I did not.
like some other investors..I believe our shorts are really disguised longs..just waiting for appropriate time to come out of the closet so to speak..after all they already own 25% of the company and no one is even talking about whether approval just when..
yes sellas..not celene..and we have no info on milestone payments and amounts except there are some..one payment from amgen being linked to start of mine phase 1..
evaluations are ignoring the 21 century cures act which according to DOC give companies like adxs a big advantage ..and anyone with vague awareness of the provisions know this.. gog phase 2 study along with statistical models could give metastazied cervical treatment early approval..while aim2serve trial continues as a preventative recurrence treatment..
Milner1..lol..at 18 cents a share and end of p3..no better short term play anywhere..lose or not..who could resist this ..10k shares for phase 3 bio with results pending for 1800.00..only way to lose here is not buying..
deals with amgen and celene add up to 900 million..celene is interesting because they engineered the adjunct therapy needed to their specifications.
shorts already control adxs with 25% of shares..by far the biggest shareholders..and they don't seem to be cashing in anytime soon..difficult to understand this share price..to discourage buying..yet anthing sub 8 and plenty of buyers..making money on the short..doesn't seem to be a priority..been over 2yrs of this..delaying adxs success..its up to fda and n.i.c.e.... deny funding..plenty of cash..seems just same old influence..harvesting a few shares until the day we begin to see revenue..yet we see 900 million in current/future revenue stream..adxs is no longer stoppable..it will file for commercialization..it is parterning with big pharma as universal adjunct treatment..why is share demand so low..that's really the question..no one willing to sell and everyone waiting for better bargain price..but this is the low. I bought more afew weeks ago at 7.8x haven't had that opp since..did pass up selling at 9+..but that's just part of longer extended pricing cycle..buying here practically guarentees 10% return minimum in a few days/weeks..thats if the price range holds..expecting more on revenue news.
Fgb well that's it..astra out bms in..thanks fgb
Since 2009..intense since Nov 2014..waiting...but am good at it..better since adxs
Shorts getting weak..even with all this negative board sentiment..sub 8 as buying opp is over..
Of course..it's easy to see big pharma owners helping out competitors with engineered adjunct treatments..long history of cooperation lol
Sorry no buyout..adxs is positioning itself as universal adjunct therapy that can be engineered to customer specification..that is what they are doing now..with partnerships..franchises..
7.63 lol maybe for 20 secs..shorts barely holding low 8s..try and but..
garyev..thanks very positive news..brighter days ahead..
big pre market trading today..whats up..
lm platform is evolving as research on identifying cancer subtypes evolve..
don't see adxs-dual as a bms consolation..but as the company said..coming out of what has been learned in developing axal..
adxs has booked 900 million over an unknown period of time and payable in unreported milestones..maybe we hear more about that at investor conference..
adxs-dual..a new construct arising from what was learned from axal..not adxs hot, or adxs mine..but adxs-dual..engineering for specific subtypes of HPV cervical cancer..we have evolved and are evolving..these subtypes already shown to be responsive to axal..now may be more treatable with this innovation..